Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Harri Kanerva"'
Publikováno v:
Int. Journal of Clinical Pharmacology and Therapeutics. 42:449-455
OBJECTIVE To study the pharmacokinetics and accumulation of deramciclane and its metabolite N-desmethylderamciclane after 60 mg twice daily doses for 4 weeks. METHODS Sixteen healthy male subjects, age range of 20-29 years, participated in this rando
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ed8f963e126d4bf622cd6fac553b6dc
https://doi.org/10.5414/cpp42449
https://doi.org/10.5414/cpp42449
Publikováno v:
Journal of Controlled Release. 95:515-520
Highly substituted starch acetate can be used to control drug release from directly compressed tablets in vitro. The aim of this study was to evaluate controlled release properties of starch acetate in vivo in humans. Three starch acetate tablet form
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::534b0cb314431743efdf67dfdf9f97ab
https://doi.org/10.1016/j.jconrel.2003.12.026
https://doi.org/10.1016/j.jconrel.2003.12.026
Publikováno v:
Biopharmaceutics & Drug Disposition. 19:531-539
The pharmacokinetics of a new serotonin 5-HT2 antagonist, deramciclane, was studied. Single oral doses of 1, 3, 6 and 10 mg kg(-1) and intravenous doses of 1, 3 and 6 mg kg(-1) were administered in beagle dogs. Moreover, the steady state pharmacokine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0714b8e3b71307751878d1a2b0c11c09
https://doi.org/10.1002/(sici)1099-081x(1998110)19:8<531::aid-bdd135>3.0.co
https://doi.org/10.1002/(sici)1099-081x(1998110)19:8<531::aid-bdd135>3.0.co
Publikováno v:
Drug Development and Industrial Pharmacy. 21:747-752
The incompatibilities in a powder mixture for the manufacture of a chewable direct compression antiplague tablet preparate, were studied. The degree of loss of chlorhexi-dine diacetate in the presence of some common tablet exci-pients was studied und
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bbf3b3005bdc09ddc1b2e33b68179c9a
https://doi.org/10.3109/03639049509048139
https://doi.org/10.3109/03639049509048139
Autor:
Jukka Penttinen, Auli Partanen, Ulla Lepola, Juha Rouru, Harri Kanerva, Tiina Pohjalainen, Hannu Koponen, Riitta H. Jokinen, Roope Raassina, Leena Lehtonen, Antti Ahokas, Outi Mäki-Ikola, Hannu Naukkarinen
Publikováno v:
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 15(6)
Deramciclane, a camphor derivative, is a novel anxiolytic agent with a unique mechanism of action. It acts as a potent and specific antagonist at serotonin 5-HT2A/2C receptors, and exhibits anxiolytic efficacy in animal models. The aim of this double
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de112672d8d703b24c58c935e5815b3b
https://pubmed.ncbi.nlm.nih.gov/15949921
https://pubmed.ncbi.nlm.nih.gov/15949921
Autor:
Imre Klebovich, George Horvai, B Gachályi, Harri Kanerva, G. Grézal, Antal Tolokán, Markku Anttila, Sándor Drabant, Viola Horváth, Samar Al-Behaisi, Katalin Balogh Nemes
Publikováno v:
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V. 58(3)
The effect of a high-fat meal on the oral bioavailability of deramciclane 30 mg tablet was evaluated in 18 healthy male volunteers in a randomised, single dose, two-way crossover study. The drug was administered following an overnight fast or a stand
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab858a9518611d5c0d8feedcda7ea09e
https://pubmed.ncbi.nlm.nih.gov/15451546
https://pubmed.ncbi.nlm.nih.gov/15451546
Autor:
Arto Urtti, Antti Helminen, Imre Klebovich, Risto Huupponen, Olavi Kilkku, Harri Kanerva, Mika Scheinin, Simo Tarpila, Sándor Drabant, Juha Rouru, Esa Heinonen
Publikováno v:
Biopharmaceuticsdrug disposition. 20(7)
The pharmacokinetics and tolerability of a new putative non-benzodiazepine type anxiolytic compound deramciclane was studied in two consecutive studies. An open dose-escalation design was used to study doses from 0.2 to 50 mg in 18 healthy male volun
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9ccc6eedbeb1ded959e4fd0dde1950e
https://pubmed.ncbi.nlm.nih.gov/10760840
https://pubmed.ncbi.nlm.nih.gov/10760840
Autor:
Saila Antila, Hannele Huuskonen, Harri Kanerva, Lasse Lehtonen, Timo Nevalainen, Paula Vanninen
Publikováno v:
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 9(1)
Site specific bioavailability and metabolism of levosimendan was studied in ten dogs by placing intestinal access port catheters in different parts of the gastrointestinal tract. 14 C-labelled levosimendan (0.1 mg/kg) was administered intravenously,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e292958bc39c95ed9c87522a83f64ea
https://pubmed.ncbi.nlm.nih.gov/10494001
https://pubmed.ncbi.nlm.nih.gov/10494001
Publikováno v:
The Journal of pharmacy and pharmacology. 50(10)
We have studied the dog model for predicting the oral absorption of deramciclane, a novel anxiolytic compound, as a model acid-labile drug. The absorption profile of deramciclane was studied in man and beagle dogs after administration of conventional
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c82e1c96dc92dacde4ba3ab6e8428a2
https://pubmed.ncbi.nlm.nih.gov/9821653
https://pubmed.ncbi.nlm.nih.gov/9821653